Atypical miRNA expression in temporal cortex associated with dysregulation of immune, cell cycle, and other pathways in autism spectrum disorders. by Ander, Bradley P et al.
UC Davis
UC Davis Previously Published Works
Title
Atypical miRNA expression in temporal cortex associated with dysregulation of immune, 
cell cycle, and other pathways in autism spectrum disorders.
Permalink
https://escholarship.org/uc/item/22p9s3ch
Journal
Molecular autism, 6(1)
ISSN
2040-2392
Authors
Ander, Bradley P
Barger, Nicole
Stamova, Boryana
et al.
Publication Date
2015
DOI
10.1186/s13229-015-0029-9
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Ander et al. Molecular Autism  (2015) 6:37 
DOI 10.1186/s13229-015-0029-9RESEARCH Open AccessAtypical miRNA expression in temporal
cortex associated with dysregulation of
immune, cell cycle, and other pathways in
autism spectrum disorders
Bradley P. Ander2, Nicole Barger1, Boryana Stamova2, Frank R. Sharp2 and Cynthia M. Schumann1*Abstract
Background: Autism spectrum disorders (ASDs) likely involve dysregulation of multiple genes related to brain
function and development. Abnormalities in individual regulatory small non-coding RNA (sncRNA), including
microRNA (miRNA), could have profound effects upon multiple functional pathways. We assessed whether a brain
region associated with core social impairments in ASD, the superior temporal sulcus (STS), would evidence greater
transcriptional dysregulation of sncRNA than adjacent, yet functionally distinct, primary auditory cortex (PAC).
Methods: We measured sncRNA expression levels in 34 samples of postmortem brain from STS and PAC to find
differentially expressed sncRNA in ASD compared with control cases. For differentially expressed miRNA, we further
analyzed their predicted mRNA targets and carried out functional over-representation analysis of KEGG pathways to
examine their functional significance and to compare our findings to reported alterations in ASD gene expression.
Results: Two mature miRNAs (miR-4753-5p and miR-1) were differentially expressed in ASD relative to control in
STS and four (miR-664-3p, miR-4709-3p, miR-4742-3p, and miR-297) in PAC. In both regions, miRNA were functionally
related to various nervous system, cell cycle, and canonical signaling pathways, including PI3K-Akt signaling, previously
implicated in ASD. Immune pathways were only disrupted in STS. snoRNA and pre-miRNA were also differentially
expressed in ASD brain.
Conclusions: Alterations in sncRNA may underlie dysregulation of molecular pathways implicated in autism. sncRNA
transcriptional abnormalities in ASD were apparent in STS and in PAC, a brain region not directly associated with core
behavioral impairments. Disruption of miRNA in immune pathways, frequently implicated in ASD, was unique to STS.
Keywords: Autism, miRNA, snoRNA, Auditory cortex, Superior temporal sulcus, Temporal lobeBackground
The autism spectrum disorders (ASDs) are heritable
neurodevelopmental conditions characterized by impair-
ments in social interaction and communication and re-
stricted, repetitive, and stereotyped patterns of behavior.
Several hundred different genetic loci, including single
gene mutations, chromosome abnormalities, and copy
number variations, have now been associated with a* Correspondence: cschumann@ucdavis.edu
1Department of Psychiatry & Behavioral Sciences, MIND Institute, University
of California at Davis Medical Center, 2805 50th Street, Sacramento, CA
95817, USA
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creativecommons.org/publicdomain/zero/1.0/growing number of diagnosed cases [1]. The genetic un-
derpinnings of the remainder of the cases are unclear,
but they are postulated as being related to the interac-
tions of multiple genes with environmental factors.
One of the questions central to the study of ASD is
how so many different genetic conditions can produce a
similar clinical phenotype. Part of the answer to this
problem appears to be that a variety of etiologically het-
erogeneous disorders converge on and disrupt key stages
of neurodevelopment that affect specific brain regions
and molecular pathways. Evidence for this has come in
part from pathway analyses of ASD candidate genes and
changes of gene expression in brain tissue [2, 3]. Severalticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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shown distinct and reproducible changes in transcrip-
tome organization [4], genetic pathways related to
neuron function and development [5–7], and immune
pathways [5] in ASD.
Given that changes in gene expression must ultimately
underlie the clinical phenotype at least to some degree,
what might be driving these changes that appear to be
region and perhaps even cell specific? Among the many
factors that can regulate gene expression—including
DNA methylation, transcription factors, and others—we
opted to examine small non-coding RNA (sncRNA) in
this study, including microRNA (miRNA) and small nu-
cleolar RNA (snoRNA). miRNA are of particular interest
because, although they do not code for protein, they
bind sequence-specific sites in target transcripts to regu-
late expression levels of mRNA and/or modulate protein
translation [8]. There is growing evidence suggesting
miRNA may play a role in ASD supported through min-
ing of SNP and CNV data [9, 10], epidemiological stud-
ies of genetic variants [11], and serum biomarker studies
[12, 13]. It is estimated that over 60 % of all genes are
regulated by miRNA because each miRNA has dozens to
hundreds of targets. For this reason, we postulated that
miRNA could play an important role in regulating the
transcriptional changes that have been reported in ASD
brain. Moreover, because miRNA (and other small and
non-coding RNA) are often cell or tissue specific and
are important in timed molecular events, they can play
critical roles in very specific aspects of neurodevelop-
ment [8]. Disturbances in a single miRNA could affect
hundreds of genes, directly, and many hundreds of
genes, indirectly, and would be one way where a single
disturbance could dramatically affect complex cellular
organization and function.
Recent whole genome expression studies show that
gene expression in brain tissue is region specific and can
reflect the distributions of major cell types including
neurons and glia [14]. In cases with no known develop-
mental disorders, neocortical transcriptional patterns are
relatively homogenous and physically closer regions typ-
ically exhibit more similar transcriptomes. However, the
primary sensory cortices appear to show the most dis-
tinct transcriptional profiles [14], suggesting that they
are transcriptionally as well as functionally distinct from
other cortical subtypes. To begin to address the under-
lying genetics of neuropathology, examination of tran-
scriptionally distinct brain regions may be crucial in
developing a precise understanding of developmental or
pathological disturbances in regulatory mRNA modula-
tors like miRNA.
To examine the expression of the small non-coding
RNAs in ASD versus typically developing brains, we fo-
cused on two functionally distinct but physically closeareas in the temporal lobe, the superior temporal sulcus
(STS) and the primary auditory cortex (PAC). The STS
is instrumental in functions critical for reciprocal social
interaction [15–17] and language [18–20] that are intim-
ately related to core features of ASD [15]. Abnormalities
in the STS have been detected in ASD including de-
creased gray matter, hypo-perfusion at resting state, and
abnormal activation during social tasks [21, 22]. In con-
trast, the PAC is a primary sensory cortex that processes
rudimentary components of sounds, e.g., auditory tone,
and may function similarly in ASD and control subjects
[23]. As such, we predicted that miRNA in PAC would
be less affected in ASD than STS. Through careful dis-
section of these two regions, isolation and examination
of expressed sncRNA, identification of regulated gene
targets, and functional interpretation of RNA, we found,
contrary to our expectation, miRNA in both regions
were altered, while no single miRNA was commonly af-
fected in both regions.
Methods
Brain tissue
This study was exempt from human subjects review by the
Internal Review Board at the UC Davis School of Medicine.
Donor brain tissue was obtained from the Autism Tissue
Program collection previously housed at the Harvard Br-
ain Tissue Resource Center (http://www.mcleanhospital.or
g/research-programs/harvard-brain-tissue-resource-center).
Postmortem Confirmation of Consent was provided by
next-of-kin and held along with identifiable personal
health information by the Autism Tissue Program. A
total of 36 samples were obtained from ten ASD and
eight control subjects. Individual and summarized
subject demographics are presented in Table 1. One
STS and one PAC sample were taken from the same
frozen coronal brain section of each donor brain. The
primary auditory cortex (PAC) sample included the
primary sensory areas of Brodmann’s areas 41 and 42
and was taken from the crown of Heschl’s gyrus
(Fig. 1), where it is reliably found as indicated by func-
tional and cytoarchitectonic maps [24]. Samples from
the superior temporal sulcus (STS) included the polymo-
dal association cortex of Brodmann’s area 22 and were
taken from the upper wall of the superior temporal sulcus
immediately opposite Heschl’s gyrus [25, 26] (Fig. 1).
RNA isolation and arrays
Total RNA was isolated from ~10 to 75 mg of dissected
brain tissue using the RecoverAll Total Nucleic Acid
Isolation Kit (Ambion) with omission of the heat de-
paraffinization step. Yields of RNA were an average of
200 ng/mg brain tissue. Quality of RNA was assessed
using the Agilent 2100 Bioanalyzer with the RNA 6000
Nano kit, and RNA quantity was measured using the
Table 1 Individual demographic information for the brain donors of samples used in this study and postmortem interval of samples
Primary diagnosis Case number Sex Age (years) Diagnostic measure PMI (hours) Primary cause of death
ASD B-7002 F 5 ADI-R 33.0 Drowning
ASD B-5342 F 11 ADI-R 12.9 Drowning
ASD B-7575 M 15 Suspected ASD 30.8 Head trauma
ASD B-6640 F 29 ADI-R 17.8 Seizure/stroke
ASD B-7762 M 30 Suspected ASD 22.9 Epilepsy
ASD B-5173 M 30 ADI-R 20.3 Gastrointestinal bleeding/seizure
ASD B-6401a M 39 ADI-R 14.0 Cardiac tamponade
ASD B-7085 F 49 Suspected ASD 21.1 Cancer
ASD B-7376b F 52 ADI-R 39.2 Unknown
ASD B-7886 M 50 ADI-R 22.7 Aspiration/seizure
ASD mean n = 10 31.0 ± 5.3 23.5 ± 2.7
CTRL B-6736 F 4 - 17.0 Acute bronchopneumonia
CTRL B-7387 M 17 - 30.8 Asphyxia/hanging
CTRL B-7738 M 24 - 35.5 Unknown
CTRL B-7369 M 36 - 26.0 Possible pulmonary embolism/MI
CTRL B-7835 F 39 - 25.3 Asphyxia/pneumonia
CTRL B-7333 M 40 - 25.3 Hepatic encephalopathy
CTRL B-8018 M 54 - 19.9 Unknown
CTRL B-8155 M 58 - 20.5 Unknown
CTRL mean n = 8 34.0 ± 6.5 25.0 ± 2.1
Demographics of each brain donor. The average ± the standard error of the mean is provided for ASD and CTRL. There were no significant differences in sex, age,
or PMI between ASD and CTRL groups
ASD autism spectrum disorders, CTRL typically developing control, PMI postmortem interval
aSTG excluded
bPAC excluded
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ance ratios ≥1.6 [27, 28], and RNA integrity numbers
ranged between 2.2 and 5.3.
Two hundred nanograms of total RNA were processed
for Affymetrix miRNA 3.0 microarrays according to the
manufacturer’s protocol and our previous publication [28].
These arrays contain probes for 5607 small non-coding
RNA including 1733 mature human miRNA, 1658 hu-
man pre-miRNA, and 2216 human snoRNA, CDBox
RNA, H/ACA Box RNA, and scaRNA. Briefly, 200 ng of
RNA is ligated to a biotinylated marker using the Flash-
Tag Biotin HSR RNA labeling kit (Affymetrix). No amp-
lification of the RNA was required during this
procedure. The samples are hybridized to the microar-
rays, and biotin is detected with streptavidin-PE. The
microarrays are scanned and fluorescent signals mea-
sured and transferred into a CEL file for subsequent
analyses. Standard quality control measures are applied,
such as excluding arrays that are significant outliers or
showing skewing in the overall intensity images. Two
samples were excluded after these tests (see Table 1). All
within chip quality control hybridization metrics on
remaining samples were within normal ranges indicating
successful sample processing.Statistics
Analyses were performed using Partek Genomics Suite
6.6 (Partek Inc., St. Louis). Cel files were imported and
normalized using Robust Multiarray Averaging (RMA)
[29]. The primary comparisons were expression differ-
ences of each sncRNA for ASD versus control cases in
the PAC and expression differences of each sncRNA for
ASD versus control in the STS. Age and postmortem
interval (PMI) were included in the following statistical
model: Yijk = μ + Primary Diagnosisi + age + PMI +
Regionj + Primary Diagnosis*Regionij + εijk, where Yijk
represents the kth observation on the ith Primary Diag-
nosis jth Region, μ is the common effect for the whole
experiment, and εijk represents the random error
component.
Statistical significance was defined as P ≤ 0.005 com-
bined with an absolute fold change ≥1.2. Inclusion of a
fold change threshold helps identify changes of biological
significance [27, 30, 31].
Unsupervised hierarchical clustering
Unsupervised hierarchical clustering was performed in
the Partek Genomics Suite in order to visualize differ-
ences of sncRNA expression between ASD and controls.
Fig. 1 Sampling of brain regions. Schematic of the human brain indicating regions of the superior temporal gyrus sampled—superior temporal
sulcus (STS - orange) and primary auditory cortex (PAC - teal). A section from the caudal portion of the temporal lobe was utilized for each case
(the approximate position is noted by the dashed lines). In the same coronal section, tissue blocks for the PAC (dark teal) were sampled from
Heschl’s gyrus (light teal) and blocks for the STS (dark orange) were sampled from the upper wall of the STS (light orange)
Ander et al. Molecular Autism  (2015) 6:37 Page 4 of 13Hierarchical clustering grouped similar sncRNA expres-
sion levels and samples into “clusters” using Euclidean
dissimilarity and average linkage method and drawing
a tree (dendrogram) that shows the hierarchy of the
clusters.
Pathway analysis
In order to examine the functional significance of the al-
tered miRNA, computationally derived targets of the
miRNA were determined. These predicted mRNA tar-
gets were then included in an over-representation
pathway analysis to determine biological functions from
the Kyoto Encyclopedia of Genes and Genomes (KEGG).
This was done using the web-based software tool
DIANA miRPath v2.0 [32]. Target genes of miRNA
lists were computationally predicted using the DIANA
microT-CDS with threshold set to 0.9. These mRNA tar-
gets were then used to determine if there were more
represented genes in a given biological pathway than
would be expected by chance using a Fisher exact test
corrected for multiple comparisons (FDR, P < 0.05) [32].
In order to contrast the biological and functional
significance of our study with studies previously report-
ing gene or gene expression lists associated with
autism spectrum disorder, we performed functional
over-representation analysis on KEGG pathways usingreported data from two prior analyses of temporal cor-
tex in ASD, Voineagu et al. (135 probes) [4] and
Garbett et al. (152 probe sets) [33], and two datasets
broadly focusing on ASD-associated genes, Pinto et al.
(139 genes) [34] and the SFARI database of positively
associated ASD genes (573 genes) [35]. Datasets were
input into the online WebGestalt tool [36] to derive
the KEGG pathway data for Fig. 5. Predicted gene tar-
gets from our study were taken from microT-CDS
after combining all brain samples (STS and PAC) and
then deriving miRNA that were different between
ASD and CTRL groups (P < 0.005, fold change > |1.2|).
Combining temporal regions allowed for a more ap-
propriate comparison to the previous studies that did
not target specific functional territories. Euler dia-
grams of area proportional overlap were generated
using eulerAPE [37].
Results
Small non-coding RNA significantly differed between ASD
and controls
There were no significant differences in the sex or age of
ASD compared to control subjects (P > 0.05, Table 1).
Table 2 lists the sncRNA that were differentially
expressed in ASD compared to controls (P < 0.005 and
fold change > |1.2|) in the temporal lobe for the superior
Table 2 Differentially expressed sncRNA between ASD and CTRL
Class of sncRNA Superior temporal sulcus Primary auditory cortex
miRNA ↑ miR-4753-5p ↑ miR-664-3p, miR-4709-3p
↓ miR-1 ↓ miR-297, miR-4742-3p
snoRNA ↑ ACA39, SNORA11C, SNORA27 ↑ (none)
↓ U13 (Chr1) ↓ SNORA22, U13 (Chr2), U13 (Chr3), U13 (Chr11), SCARNA6
Stem-loop precursor miRNA ↑ mir-1204, mir-1913, mir-605, mir-3152, mir-4730 ↑ mir-3158-1, mir-3194, mir-4314, mir-4436a
↓ mir-1287, mir-19b-1, mir-4490 ↓ mir-138-2, mir-146b, mir-548 g
Small non-coding RNA (sncRNA) that had significant changes in expression in the superior temporal sulcus (STS) and primary auditory cortex (PAC) of ASD brains
compared to control brains (P < 0.005 and fold change > |1.2|)
miRNA microRNA, sncRNA small non-coding RNA, snoRNA small nucleolar RNA
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tex (PAC) (detailed fold change and P values provided in
Additional file 1: Tables S1 and S2). When subjected to
hierarchical clustering, these sncRNA completely sepa-
rated ASD from control subjects for both the PAC and
STS brain regions (Fig. 2), lending further support that
these sncRNA were significantly different in ASD com-
pared to controls in both brain regions.
For the STS, there were 14 sncRNA differentially
expressed between ASD and control brains (Table 2). Of
the two mature miRNA, miR-4753-5p increased expres-
sion and miR-1 decreased expression (Fig. 3, Table 2).
For the PAC, there were 16 sncRNA differentially expressed
between ASD and control brains (Table 2). Of the four
mature miRNA, miR-664-3p and miR-4709-3p increased
expression and miR-297 and miR-4742-3p decreased ex-
pression (Fig. 3, Table 2).
Small nucleolar RNA (snoRNA), another class of small
non-coding RNA, were also differentially expressed be-
tween ASD and control brains. ACA39, SNORA11C,
and SNORA27 increased in STS while the U13 paralog
on chromosome 1 decreased expression in STS (Table 2).
In PAC, no snoRNA had increased expression, whereas
SNORA22, SCARNA6, and three U13 paralogs on chro-
mosomes 2, 3, and 11 showed decreased expression in
ASD compared to controls (Table 2). Eight pre-miRNA
changed expression in the STS, and seven pre-miRNA
changed expression in the PAC in ASD compared to
controls (Table 2).Functional roles of miRNA in the STS and PAC
Based on the microT-CDS algorithm (which includes
coding and 3′ UTR sequences, threshold = 0.9), we
found miRNA differentially expressed in ASD had 1214
predicted gene targets in PAC and 445 in STS (Additional
file 1: Table S3). Over represented KEGG pathways that
contained more gene targets than expected by chance
(Fisher exact test, FDR corrected P < 0.05) are summarized
in Fig. 4. KEGG pathways regulated by these miRNA
showed little overlap between regions (Fig. 4). Indeed, onlytwo pathways were shared between PAC and STS: “path-
ways in cancer”, which are cell cycle, cell differentiation,
mitochondrion, and gene regulation focused, and the PI3K-
Akt signaling pathway (Fig. 4). Another major finding is
that immune pathways under control of the differentially
expressed miRNA appear to be dysregulated only in STS
whereas neuronal, cell cycle, signaling and cell processes
were dysregulated in both PAC and STS in ASD compared
to control subjects (Fig. 4).
Figure 5 shows that many of the predicted brain
miRNA-regulated pathways in the STS and PAC-
combined analysis in this study were also predicted to
be dysregulated based on genes identified in the expres-
sion studies of Voineagu et al. [4] and Garbett et al. [33]
as well as pathways implicated in ASD gene sets from
Pinto et al. [34] and the SFARI gene database [35]. The
significance of the overlap of our data to each of these
data sets was P < 0.05 using the hypergeometric prob-
ability function phyper in R.Discussion
This study provides the first evidence of alterations in
expression of specific small regulatory non-coding RNA
in the temporal cortex of autism spectrum disorder
(ASD) brains. The major findings include the following:
1) There are differences in miRNA, snoRNA, and pre-
cursor miRNA in both the association cortex of the su-
perior temporal sulcus (STS) and the primary auditory
cortex (PAC). While the STS is involved in functions as-
sociated with the core features of ASD, the many
changes in sncRNAs in primary auditory cortex were
not expected as it is not functionally associated with
core deficits of ASD. 2) Functional pathways for the
gene targets of dysregulated miRNA across both regions
were associated with nervous system, cell cycle, cell sig-
naling, and other processes. 3) miRNAs that regulate im-
mune functions were only altered in STS, supporting a
role for immune dysfunction in STS associated with the
core social deficits of autism. Even a few dysregulated
miRNA and other sncRNAs have the potential to affect
Fig. 2 Relative expression of sncRNA in STS and PAC of ASD and CTRL subjects. Heat maps showing hierarchical clustering of dysregulated small
non-coding RNAs on the X axis for ASD and control (CTRL) subjects on the Y axis for the superior temporal sulcus (STS) (upper panel) and the
primary auditory cortex (PAC) (lower panel). Note that the ASD and CTRL subjects cluster together in both the PAC and STS. Bright red color
indicates a relative twofold increase in expression for the particular sncRNA, and a bright green color indicates a relative twofold decrease in
expression across ASD and control subjects (see bar at bottom of lower panel)
Ander et al. Molecular Autism  (2015) 6:37 Page 6 of 13transcription and/or translation of hundreds of target
genes and affect brain signaling, connectivity, and
behavior.
Differentially expressed sncRNA in both primary and
association cortex in ASD
As hypothesized, based on functional and structural dif-
ferences known to be present in ASD STS, we found
that the STS contained differentially expressed regula-
tory sncRNA. One mature miRNA, miR-4753-5p, exhib-
ited increased expression levels and another, miR-1, had
decreased expression in ASD relative to control tissue.
Five immature, stem-loop precursor miRNA showed in-
creased expression, and three had decreased expression
in the STS. Given their regulatory role, miRNA canimpact hundreds of gene targets and can greatly influ-
ence expression levels of mRNA and protein translation
[8], potentially making a substantial contribution to
differences in overall gene expression levels in ASD.
There were also differences in a number of small nu-
cleolar RNAs (snoRNAs) in STS in ASD. snoRNAs are
small RNA molecules that act to guide chemical modifi-
cations of other RNAs including ribosomal RNAs, trans-
fer RNAs, and small nuclear RNAs. Three snoRNAs,
including ACA39, SNORA11C, SNORA27, exhibited in-
creased expression, and one, U13 (Chr1), had decreased
levels. Functionally, sequences within snoRNAs target
them to specific mRNA targets, with the C/D box snoR-
NAs methylating target bases and H/ACA box snoRNAs
being associated with pseudouridylation of target bases.
Fig. 3 Expression levels of significant miRNA is STS and PAC. Expression levels of microRNA (miRNA) that had significantly increased or decreased
expression in ASD compared to control subjects in the superior temporal sulcus and in the primary auditory cortex (P< 0.005 and fold change > |1.2|).
ASD values are in red, and control (CTRL) values are in blue. Note that individual subjects are plotted along with box and whisker plots, and the size of the
diamonds for each individual corresponds to age of the subject
Ander et al. Molecular Autism  (2015) 6:37 Page 7 of 13These modifications likely affect translation as well as
RNA silencing, telomerase maintenance, and alternative
splicing [38]. For example, U13 is involved in proper for-
mation of the 3′ end of the 18S ribosomal subunit [39],
potentially impacting protein translation and alternative
splicing. Aberrant expression of U13 could have wide-
spread cellular effects in the brain. We find that non-
coding snoRNAs along with non-coding miRNA are
dysregulated in ASD brain, while other studies havealso implicated long non-coding RNAs in ASD neuro-
pathology [40, 41].
To our knowledge, there have not been any previous
studies targeting molecular abnormalities specifically in
primary sensory cortex of ASD brains, making this the
first report suggesting regulatory abnormalities in a
primary sensory region. In PAC, two mature miRNAs
exhibit increased expression, miR-664-3p and miR-
4709-3p, and two decreased expression, miR-4742-3p
Fig. 4 Functional categorization of miRNA target genes. KEGG pathways of the predicted gene targets of the microRNA that showed altered
expression in ASD compared to control subjects in the PAC and in the STS. These pathways had more predicted regulated target genes in
the pathway than would have been expected by chance (P < 0.05). Pathways are grouped according to categories in vertical text. Only miRNA
differentially expressed in STS had target genes over-represented in immune related pathways and functions
Ander et al. Molecular Autism  (2015) 6:37 Page 8 of 13and miR-297. Five snoRNAs showed decreased expression,
including SNORA22, SCARNA6, and three paralogs of
U13. Four stem-loop precursors were additionally up-
regulated, while three had decreased expression.It is notable that three of the identified precursor
miRNA have been previously associated with ASD. miR-
4436 has been described as a candidate susceptibility
miRNA gene in autism [42]. miR-548 is dysregulated in
Fig. 5 Functional similarities to other studies looking at ASD-related genes. Overlap of KEGG pathways identified through analysis of mRNA targets of brain
miRNA in ASD and control brain from the STS and PAC combined analysis with previously published and compiled gene lists associated with ASD in (a)
studies with transcriptional measurements of ASD brain (Garbett et al. [33] and Voineagu et al. [4]) and (b) sets of genes associated with ASD (Pinto et al.
[34] and Abrahams et al. (SFARI) [35]). Numbers indicate KEGG pathways significantly over-represented by mRNA in the respective data set. The 44 KEGG
pathways overlapping between this study, SFARI, and Pinto et al. appear in Additional file 1: Table S4
Ander et al. Molecular Autism  (2015) 6:37 Page 9 of 13ASD lymphoblastoid cell lines [43] and targets genes as-
sociated with several pathways implicated in ASD in-
cluding ubiquitin, Wnt, axon guidance, LTP, and natural
killer cells [30]. Additionally, it can regulate host anti-
viral responses via direct targeting of IFN-λ1 [44], which
may have relevance for maternal immune activation
models of ASD and other neurodevelopmental disorders
[45, 46]. miR-146 is reported to have altered expression
in ASD cerebellar cortex [47] and in ASD lymphoblas-
toid cell lines. In the nervous system, miR-146 (a,b)
modulates AMPA receptor endocytosis [48] and glial
proliferation via Notch signaling [49]. miR-146 also in-
fluences the activation state of brain microglia [50].
Microglia are reported to increase in number, show evi-
dence of activation, and show increased gene expression
in ASD post-mortem brain tissue [51–55]. Moreover,
deficiencies in neuron-microglia signaling result in im-
paired functional brain connectivity and can influence
social behavior [56]. Although the functional importance
of immature miRNA is not clear, the mature forms of
the three stem-loop precursors found in the PAC have
previously been associated with ASD.
A number of the predicted gene targets of the miRNA
we found different between ASD and typically develop-
ing STS have previously been identified in studies look-
ing at gene expression in the temporal cortex [4, 33].
These target genes (INHBA, WDR1, TAGLN2, FNDC3B,
ZFP36L1, CNN3, CPLX2, ZNF365, and GLS2) have im-
portant roles including those related to “cell communi-
cation and motility” and “cell fate and differentiation.”
As we observed decreased miR-1 expression and in-
creased miR-4753-5p expression in our study, we would
expect to find higher and lower expression of the re-
spective gene transcripts they target in STS. The regula-
tion of these genes and others by altered patterns ofmiRNA may be at least in part responsible for regional
and cellular differences that shape the social and behav-
ioral phenotypes associated with ASD.
Dysregulation of sncRNAs in the PAC of ASD brain is
a novel molecular finding we did not predict. Although
sensory dysfunction is not considered a core diagnostic
feature, neurophysiological studies have reported audi-
tory abnormalities in ASD patients. Abnormalities in
cortical auditory-evoked potentials have been reported
when sound is presented to the left ear [57]. In contrast,
speech stimulation does not produce fMRI abnormalities
in PAC of individuals with ASD [23]. Atypical vertical
sound localization and sound-onset sensitivity evidenced
in ASD cases likely involves primary auditory areas [58].
In addition, a magnetoencephalography study examining
differences in auditory cortex function in young ASD
and TD children found that there is atypical brain func-
tion in the auditory cortex in young children with ASD,
regardless of language development [59]. Coupled with
neurophysiological findings, the dysregulated sncRNA in
PAC in this study provide additional evidence for PAC
dysfunction in ASD. Increased attention to primary
cortices may be warranted in future investigations of
ASD, as such dysfunction could conceivably contribute
to cognitive impairments in complex social and linguis-
tic tasks.
miRNA targets incorporated into pathways associated
with ASD pathogenesis
We postulated that miRNA play an important role in
regulating the transcriptional changes that have been re-
ported in ASD brain tissue. Several genomic and gene
expression studies of ASD brain have shown distinct and
reproducible differences from typically developing cases
that involve neurons/synapses and the immune system.
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ences in transcriptome organization between ASD and
typically developing brain by gene co-expression analysis
[4]. Moreover, two main modules of co-expressed genes
in ASD brain were identified including a neuronal/syn-
apse module that was associated with genes identified by
GWAS in ASD and an immune module that was not
associated with ASD GWAS genes [4, 60]. These data
supported prior studies of neuron, glia, and immune
abnormalities in ASD brain [33, 51, 61–67]. Another re-
cent whole genome study showed age-related differences
of gene expression in ASD brain that also affected
neuron and immune pathways including neurogenesis,
cell cycle, cell differentiation, cell death, and immune re-
sponse in young ASD brain [5]. A recent study used
weighted gene co-expression network analysis (WGCNA)
combined with ASD candidate genes to suggest that cor-
tical projection neurons in layers V and VI of prefrontal/
frontal cortex during 10–24 weeks post-conception were
key cells in ASD pathogenesis [6]. In a similar WGCNA
analysis using different ASD candidate genes, the superficial
(pyramidal) glutamatergic cortical projection neurons were
implicated in ASD pathogenesis [7].
We found many pathways associated with differentially
expressed miRNA in ASD temporal cortex were similarly
associated with nervous system and immune function, as
well as basic cellular processes previously reported to be
dysregulated in ASD. Of the 34 predicted pathways and
processes that were represented in the target genes of
miRNA in STS and PAC (Fig. 4), a number have been im-
plicated in previous ASD studies including glutamatergic,
dopaminergic, and cholinergic synapse pathways, axon
guidance, synaptic vesicle cycling, neurotrophins, immune
pathways, hedgehog and Wnt signaling, spliceosome, and
RNA degradation [2–4, 27, 60]. Comparing our broader
temporal cortex findings with previous analyses, it is not-
able that 44 of the 75 pathways regulated by differentially
expressed miRNA in our study are shared with the 57 path-
ways reported to be affected by copy number variants in
ASD [34] (Fig. 5, Additional file 1: Table S4). Moreover, we
found 7 and 15 pathways, respectively, are shared with the
16 and 24 pathways reported to demonstrate alterations in
the two prior analyses of mRNA expression ASD temporal
cortex [4, 33] (Fig. 5). Common functions associated with
pathways across all studies of ASD temporal cortex include
cell cycle, metabolic, and neuron-related pathways and
processes. Given the substantial number of convergent
pathways between studies of temporal cortex mRNA and
miRNA expression, it is highly plausible that miRNA are
exerting a regulatory influence over mRNA associated with
atypical cortical function in ASD.
Within the temporal lobe, two pathways were shared
between PAC and STS, the “PI3K-Akt pathway” and “path-
ways in cancer.” The PI3K-Akt pathway is of interest as ithas been implicated in a number of previous ASD studies.
The PI3K-Akt/mTOR pathway is dysregulated in mono-
genic disorders associated with ASD including Fragile X,
tuberous sclerosis, neurofibromatosis, and PTEN [68]. Rare
and even some common genetic variants associated with
ASD affect PI3K-Akt signaling [2, 69]. Studies of gene ex-
pression in blood of ASD subjects have found abnormal
PI3K-Akt/mTOR signaling [70]. Our studies of alternative
splicing of mRNA expressed in blood leukocytes detected
abnormalities of PI3K-Akt signaling in about half the 2–4
year old ASD children with idiopathic ASD [27]. Thus, the
current study suggests abnormal PI3K-Akt signaling in
temporal cortex of ASD subjects in both primary auditory
and STS association cortex, and previous studies suggest
PI3K-Akt abnormalities in blood and differential alternative
splicing of PI3K-Akt pathways in blood of many ASD sub-
jects. These results would support this as a potential thera-
peutic target in at least a subgroup of ASD subjects as has
been suggested by others [71].
One of the major findings of this study is that few pre-
dicted miRNA-regulated pathways were shared between
the PAC and STS, despite the fact that they are adjacent
cortical structures. Because many pathways are specific
for PAC or STS, there is evidence that differential regu-
lation of miRNA, their mRNA targets, and associated
pathways can be region specific in ASD.
Differentially expressed miRNA having a significant
number of gene targets in immune and most of the
cell cycle KEGG pathways (except “pathways in can-
cer”) were restricted only to STS. Cell cycle genes
might be related to neuronal cell death and/or to glial
proliferation and perhaps linked to increased microglial
and neuron numbers in ASD brain [51–53, 63, 72]. Ob-
served immune pathways in this study, related to both
viruses and bacteria, are consistent with many reports
of immune pathway activation in ASD brain and blood
[4, 5, 33, 60, 73–75]. Since the immune regulated genes
in ASD brain were not among the GWAS-associated
ASD genes [4], these immune genes might reflect the
environmental factor in ASD pathogenesis. ASD is
considered to be a complex genetic disorder in which
several genes interact with an environmental precipi-
tant. Activation of immune and cell cycle pathways in
STS might suggest that this is a region of primary
pathology, and lack of immune and cell cycle activation
in PAC might suggest gene changes in PAC are sec-
ondary to those in STS association cortex because of
interconnections between the two regions. At the very
least, these findings suggest molecular and immune
disruption pathologies present in the temporal associ-
ation cortex that are not shared with primary sensory
cortex. This further emphasizes the importance of
assessing molecular abnormalities in distinct cortical
regions.
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Future studies will need to confirm the miRNA changes
discovered here with microarrays using qRT-PCR,
though in other studies we have shown most miRNA
regulated on arrays can be confirmed using qRT-PCR
[28]. In addition, future studies will need to confirm the
changes in a separate cohort, to examine mRNA targets
of the miRNA and their associated pathways, and to
examine other cortical regions which may also be associ-
ated with core ASD symptoms. Future studies of primar-
ily young brains are needed to assess changes around
the time of diagnosis, though postmortem studies like
this by their nature tend to have older subjects. Though
age, gender, and other factors were included in the stat-
istical model, some covariates like medications, cause of
death, and others could not be included because of the
limited number of samples.
Conclusions
This study provides the first demonstration of dysregula-
tion of sncRNA in superior temporal cortex of ASD
brains that could regulate hundreds of target transcripts
and many predicted pathways and processes that have
been implicated in previous ASD studies. In addition to
changes in sncRNA expression in the STS, transcrip-
tional dysregulation in the PAC could play a role in
social and language dysfunction in ASD. This has impli-
cations for understanding the pathogenesis of ASD and
ascertaining whether the “primary ASD pathology” is
only in association cortex and whether abnormalities of
both primary auditory cortex and STS temporal associ-
ation cortex contribute to social and language behavioral
dysfunction observed in ASD.
Additional file
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